Orforglipron, a biased partial agonist of the GLP-1R with lower activation of the β-arrestin pathway (28), resulted in body weight reductions up to 12.6% (placebo adjusted) at 36 weeks in obese non-diabetic patients (29) while Danuglipron, a GLP-1R full agonist achieved approximately up to 4-5% body weight lowering at 16 weeks in T2D (30, 31). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.